Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214567 | 0.91 | HDAC1 (0.53) | NAMPTHDAC1HDAC6BRD4CTNNB1 | |
| SCHEMBL2212049 | 0.89 | NAMPT (0.46) | NAMPTHDAC1HDAC6CFTRKDM1A | |
| SCHEMBL2213295 | 0.88 | NAMPT (0.49) | NAMPTHDAC1HDAC6BRD4 | |
| SCHEMBL2216236 | 0.87 | KLKB1 (0.41) | HDAC1KDM1A | |
| SCHEMBL2213575 | 0.86 | HDAC1 (0.46) | NAMPTHDAC1HDAC6 | |
| SCHEMBL2214428 | 0.85 | NAMPT (0.46) | NAMPTHDAC1HDAC6 | |
| SCHEMBL2212020 | 0.84 | NAMPT (0.46) | NAMPTHDAC1HDAC6CFTRBRD4 | |
| SCHEMBL2213915 | 0.83 | HDAC1 (0.47) | NAMPTHDAC1HDAC6 | |
| SCHEMBL2212158 | 0.83 | NAMPT (0.43) | NAMPTHDAC1HDAC6CFTR | |
| SCHEMBL2211305 | 0.82 | NAMPT (0.47) | NAMPTHDAC1HDAC6CCKBRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1797096-A2 | NOVEL PYRAZOLOPYRIMIDINES | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027346-A2 | NOVEL PYRAZOLOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | NAMPT 2045/4885HDAC1 1147/4885HDAC6 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.